Peripheral Vascular Disease
Early Studies by Miley listed the treatments of disorders caused by vascular blockage in the legs and arms. In some cases UBI reversed the need for amputation of gangrenous toes and feet, by reversing hopeless swelling and cyanosis.
Two UBI treatments were use for a man who had two gangrenous toes were removed. The patient convalesced and was able to return to work. He was undergoing treatment with UBI on a quarterly basis. Upon stopping treatment, Buerger’s disease appeared again. Two more UBI treatments were given again and the pain disappeared.
(Miley, “Ultraviolet Blood Irradiation…”)
Thirteen cases of thrombophlebitis were treated at the Clinic of Hahnemann Medical College and Hospital in Philadelphia. The first 5 cases were treated with drugs and therapy, these failed and didn’t produce positive results. UBI treatments were then administered and first pain disappeared, then fever, and lastly edema.
(Miley, “The Control of Acute…”)
Double Blind Study of 50 patients in Fontaine Stage II of arterial disease.
Group 1 – 16 weeks of drug therapy distance walking improved 160%
Group 2 – 4-6 weeks inpatient therapy increased 100%
Group 3 – 6 day placebo with UBI (no light) 90% improvement
Group 4 – 6 day real UBI treatment – 360% improvement
Results confirmed in 18 subsequent trials and reports. Smoking and diabetes patients were more difficult and required more UBI treatments.
(Frick, “Fibel der Ultrviolettbestrahlung…”)
Results are markedly superior to a standard drug regime. Drugs for intermittent claudication, like pentoxifylline (Trental), only show a 19-65% increase in walking distance.
The following considers LBI treatment of 28 patients. Another group of 30 patients, acting as controls in the study, receive standard treatment.
LBI Standard Drug Therapy
43% significant improvement 33% significant improvement
50 % benefited 16.7% benefited
7% no response 50% no response